S. Hassan

发表

Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial

D. Dearnaley, C. Parker, M. Mason, 2022, The Lancet. Oncology.

Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial (CRUK/06/016).

D. Dearnaley, V. Khoo, J. Logue, 2016 .

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Annie Gao, Clare Griffin, John Staffurth, 2016, The Lancet. Oncology.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

Annie Gao, John Staffurth, Peter Kirkbride, 2012, The Lancet. Oncology.

Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer

D. Dearnaley, C. Parker, C. Cruickshank, 2018, Clinical and translational radiation oncology.

PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018)

J. Staffurth, A. Henry, C. Cruickshank, 2020, Clinical and translational radiation oncology.

PEARLS – A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA‐avid pelvic and/or para-aortic lymph nodes at presentation

J. Staffurth, E. Miles, C. Cruickshank, 2022, Clinical and translational radiation oncology.

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity

D. Dearnaley, V. Khoo, S. Hassan, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.

D. Dearnaley, V. Khoo, C. Clark, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

8LBA 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group

D. Dearnaley, V. Khoo, J. Logue, 2015 .

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

D. Dearnaley, V. Khoo, C. Parker, 2016, The Lancet. Oncology.

Title Radiotherapy Quality Assurance for the CHHiP Trial : Conventional versus Hypofractionated High-dose Intensity-modulated Radiotherapy in Prostate Cancer

D. Dearnaley, V. Khoo, C. Clark, 2019 .